Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib

被引：0
|
作者：
Belani, Neel
Rizwan, Farsha
Hasler, Jill
Bauman, Jessica
Mitchell, Khadijah
Borghaei, Hossein
Bodor, Joseph N.
机构：
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2024年 / 33卷 / 09期
关键词：
D O I：
10.1158/1538-7755.DISP24-A087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A087
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [2] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [3] Osimertinib in EGFR-Mutated Advanced NSCLC
    Yan, Kelvin
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1863 - 1863
  • [4] Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC
    Tanaka, Ichidai
    Gen, Soei
    Hori, Kazumi
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Ishii, Makoto
    CANCER SCIENCE, 2025, 116 : 329 - 329
  • [5] Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC
    Lee, M.
    Miao, E.
    Zhang, C.
    Xue, X.
    Tuckman, S.
    Halmos, B.
    Cheng, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S331 - S332
  • [6] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
  • [7] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S-W
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdiviezo, N.
    Ahmed, S.
    Maurel, J-M
    Andrasina, I
    Goldman, J.
    Ghiorghiu, D.
    Rukazenkov, Y.
    Todd, A.
    Kobayashi, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 1935 - 1948
  • [8] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
  • [9] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [10] Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC
    Lee, Matthew
    Miao, Emily
    Zhang, Chenxin
    Xue, Xiaonan
    Tuckman, Steven
    Halmos, Balazs
    Cheng, Haiying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345